Cargando…

Current Concepts on Pathogenic Mechanisms and Histopathology in Cutaneous Lupus Erythematosus

Cutaneous lupus erythematosus (CLE) is an interferon (IFN)-driven autoimmune disease that may be limited to the skin or can be associated with systemic lupus erythematosus (SLE). CLE occurs in several morphologic subtypes ranging from isolated, disc-shaped plaques to disseminated skin lesions. The t...

Descripción completa

Detalles Bibliográficos
Autores principales: Fetter, Tanja, Braegelmann, Christine, de Vos, Luka, Wenzel, Joerg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196867/
https://www.ncbi.nlm.nih.gov/pubmed/35712102
http://dx.doi.org/10.3389/fmed.2022.915828
_version_ 1784727276540133376
author Fetter, Tanja
Braegelmann, Christine
de Vos, Luka
Wenzel, Joerg
author_facet Fetter, Tanja
Braegelmann, Christine
de Vos, Luka
Wenzel, Joerg
author_sort Fetter, Tanja
collection PubMed
description Cutaneous lupus erythematosus (CLE) is an interferon (IFN)-driven autoimmune disease that may be limited to the skin or can be associated with systemic lupus erythematosus (SLE). CLE occurs in several morphologic subtypes ranging from isolated, disc-shaped plaques to disseminated skin lesions. The typical histopathologic pattern of skin lesions is named interface dermatitis and characterized by a lymphocytic infiltrate and necroptotic keratinocytes at the dermo-epidermal junction. Other histopathologic patterns primarily involve the dermis or subcutis, depending on the subtype. One critical mechanism in CLE is the chronic reactivation of innate and adaptive immune pathways. An important step in this process is the recognition of endogenous nucleic acids released from dying cells by various pattern recognition receptors (PRRs), including Toll-like receptors (TLRs) and other cytosolic receptors. Crucial cells in CLE pathogenesis comprise plasmacytoid dendritic cells (pDCs) as major producers of type I IFN, T cells exerting cytotoxic effects, and B cells, previously believed to contribute via secretion of autoantibodies. However, B cells are increasingly considered to have additional functions, supported by studies finding them to occur in highest numbers in chronic discoid lupus erythematosus (CDLE), a subtype in which autoantibodies are often absent. More precise knowledge of how CLE subtypes differ pathophysiologically may allow a tailored pharmacotherapy in the future, taking into account the specific molecular signature in relation to the morphologic subtype.
format Online
Article
Text
id pubmed-9196867
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91968672022-06-15 Current Concepts on Pathogenic Mechanisms and Histopathology in Cutaneous Lupus Erythematosus Fetter, Tanja Braegelmann, Christine de Vos, Luka Wenzel, Joerg Front Med (Lausanne) Medicine Cutaneous lupus erythematosus (CLE) is an interferon (IFN)-driven autoimmune disease that may be limited to the skin or can be associated with systemic lupus erythematosus (SLE). CLE occurs in several morphologic subtypes ranging from isolated, disc-shaped plaques to disseminated skin lesions. The typical histopathologic pattern of skin lesions is named interface dermatitis and characterized by a lymphocytic infiltrate and necroptotic keratinocytes at the dermo-epidermal junction. Other histopathologic patterns primarily involve the dermis or subcutis, depending on the subtype. One critical mechanism in CLE is the chronic reactivation of innate and adaptive immune pathways. An important step in this process is the recognition of endogenous nucleic acids released from dying cells by various pattern recognition receptors (PRRs), including Toll-like receptors (TLRs) and other cytosolic receptors. Crucial cells in CLE pathogenesis comprise plasmacytoid dendritic cells (pDCs) as major producers of type I IFN, T cells exerting cytotoxic effects, and B cells, previously believed to contribute via secretion of autoantibodies. However, B cells are increasingly considered to have additional functions, supported by studies finding them to occur in highest numbers in chronic discoid lupus erythematosus (CDLE), a subtype in which autoantibodies are often absent. More precise knowledge of how CLE subtypes differ pathophysiologically may allow a tailored pharmacotherapy in the future, taking into account the specific molecular signature in relation to the morphologic subtype. Frontiers Media S.A. 2022-05-30 /pmc/articles/PMC9196867/ /pubmed/35712102 http://dx.doi.org/10.3389/fmed.2022.915828 Text en Copyright © 2022 Fetter, Braegelmann, de Vos and Wenzel. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Fetter, Tanja
Braegelmann, Christine
de Vos, Luka
Wenzel, Joerg
Current Concepts on Pathogenic Mechanisms and Histopathology in Cutaneous Lupus Erythematosus
title Current Concepts on Pathogenic Mechanisms and Histopathology in Cutaneous Lupus Erythematosus
title_full Current Concepts on Pathogenic Mechanisms and Histopathology in Cutaneous Lupus Erythematosus
title_fullStr Current Concepts on Pathogenic Mechanisms and Histopathology in Cutaneous Lupus Erythematosus
title_full_unstemmed Current Concepts on Pathogenic Mechanisms and Histopathology in Cutaneous Lupus Erythematosus
title_short Current Concepts on Pathogenic Mechanisms and Histopathology in Cutaneous Lupus Erythematosus
title_sort current concepts on pathogenic mechanisms and histopathology in cutaneous lupus erythematosus
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9196867/
https://www.ncbi.nlm.nih.gov/pubmed/35712102
http://dx.doi.org/10.3389/fmed.2022.915828
work_keys_str_mv AT fettertanja currentconceptsonpathogenicmechanismsandhistopathologyincutaneouslupuserythematosus
AT braegelmannchristine currentconceptsonpathogenicmechanismsandhistopathologyincutaneouslupuserythematosus
AT devosluka currentconceptsonpathogenicmechanismsandhistopathologyincutaneouslupuserythematosus
AT wenzeljoerg currentconceptsonpathogenicmechanismsandhistopathologyincutaneouslupuserythematosus